Troy E. Fuller
Zoetis
15 Papers
176 Citations
Troy E. Fuller is an academic researcher from Zoetis. The author has contributed to research in topics: Actinobacillus pleuropneumoniae & Virulence. The author has an hindex of 7, co-authored 14 publications. Previous affiliations of Troy E. Fuller include Michigan State University & Upjohn.
Chat about Author
Papers
Identification of in vivo induced genes in Actinobacillus pleuropneumoniae.
TL;DR: An in vivo expression technology (IVET) system to identify Actinobacillus pleuropneumoniae gene promoters that are specifically induced in vivo during infection is developed, the first report of an IVET system for use in the family Pasteurellaceae, as well as the first reported of anIVET system utilizing an infection model of pneumonia in the natural host.
53
A riboflavin auxotroph of Actinobacillus pleuropneumoniae is attenuated in swine.
TL;DR: The first demonstration of the attenuation of A. pleuropneumoniae by introduction of a defined mutation in a metabolic gene and the first demonstration that mutations in the genes required for riboflavin biosynthesis can lead to attenuation in a bacterial pathogen are demonstrated.
45
Characterization of actinobacillus pleuropneumoniae riboflavin biosynthesis genes
Troy E. Fuller,Martha H. Mulks +1 more
TL;DR: The identification, cloning, and complete nucleotide sequence of four genes from Actinobacillus pleuropneumoniae that are involved in riboflavin biosynthesis are reported, which can specify production of large amounts of rib oflavin in Escherichia coli.
35
A genetically-defined riboflavin auxotroph of Actinobacillus pleuropneumoniae as a live attenuated vaccine.
TL;DR: It is demonstrated that immunization with live avirulent riboflavin auxotrophs could elicit significant protection against experimental challenge with both homologous and heterologous virulent serotypes of A. pleuropneumoniae.
31
Patent
Riboflavin mutants as vaccines against actinobacillus pleuropneumoniae
Troy E. Fuller,Martha H. Mulks,Brad J. Thacker +2 more
- 28 Oct 1997
TL;DR: In this article, a vaccine against Actinobacillus pleuropneumoniae (APP) comprising genetically defined biochemically attenuated mutant of APP that requires riboflavin and is attenuated in vivo.
9